Context Therapeutics Inc.
NASDAQ:CNTXBiotechnology
+$0.02 today
- Market cap
- $63.67M
- Beta
- 1.61
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$0.42
Volume 1.71M
Average 1.16M
CNTX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Context Therapeutics Inc.NASDAQ: CNTX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $8.68M (cash outflow) rose 89.6% year over year, ahead of the +45.6% change in trailing-twelve-month net income. Sequentially, it fell 33.4% from the prior quarter. Over 3 fiscal years it compounded at +34.5% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$39.42M (+9.1%) for the fiscal year ending Dec 2026, a slowdown from the +35.2% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.68M-33.4% QoQ
- Last fiscal yearDec 2025
- -$36.12M+35.2% YoY
- LTMMar 2026
- -$40.23M+45.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +89.6% | +2.4% | -87.2 pp |
| 1 year | +35.2% | +9.1% | -26.0 pp |
| 3-year CAGR | +34.5% | +21.7% | -12.9 pp |
| 5-year CAGR | +8.0% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (36.12M) USD
- Year-over-year change
- -35.2%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (36.12M) | -35.2% |
| FY2024 | 2024-12-31 | (26.73M) | -11.5% |
| FY2023 | 2023-12-31 | (23.96M) | -61.5% |
| FY2022 | 2022-12-31 | (14.84M) | -41.9% |
| FY2021 | 2021-12-31 | (10.46M) | — |
Net Income vs competitors
How CNTX compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +45.6% is the 3rd highest of 10, against a peer median of +8.1%.
- Over three fiscal years its annual growth of +34.5% compares with a peer median of -14.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $110M USD | +489.6% | — | — | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| FY2025 | $55.48M USD | +255.0% | -21.8% | 86687.5% | |
| LTM Mar 2026 | $49.87M USD | -29.4% | -21.8% | 4987.4% | |
IMAImageneBio Inc | LTM Mar 2026 | $45.07M USD | +8.1% | -8.7% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $44.1M USD | — | +41.0% | — |
| LTM Mar 2026 | €41.2M EUR | -7.9% | +14.1% | 140477.1% | |
| LTM Mar 2026 | $40.23M USD | +45.6% | +34.5% | — | |
| LTM Mar 2026 | $33.51M USD | +15.3% | -4.4% | 25009.7% | |
| LTM Mar 2026 | $24.17M USD | -3.2% | -31.5% | 339.3% | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $20.6M USD | -67.7% | -30.2% | 288.3% |
| Peer median (excluding CNTX) | — | +8.1% | -14.6% | 4987.4% | |
Competitors are the stored peer set for CNTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.46M) | (14.84M) | (23.96M) | (26.73M) | (36.12M) |
| Depreciation & Amortization | 0 | 9.27K | 12.04K | 10.88K | 16.25K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 511.08K | 976.44K | 1.08M | 841.87K | 1.33M |
| Change in Working Capital | (2.22M) | (277.52K) | 1.78M | (3.48M) | 6.28M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (866.01K) | (787.89K) | 1.45M | (946K) | 1.1M |
| Other Working Capital | (1.36M) | 510.37K | 329.03K | (2.53M) | 5.19M |
| Other Non-Cash Items | 3.37M | 578.52K | 51.97K | 14.79M | 2.11M |
| Operating Cash Flow | (8.8M) | (13.55M) | (21.05M) | (14.56M) | (26.39M) |
| Capital Expenditures | (250K) | (536.84K) | 0 | (14.76M) | (33.95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (14.75M) | (2M) |
| Investing Cash Flow | (250K) | (536.84K) | 0 | (14.76M) | (2.03M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 53.41M | (102.07K) | 0 | 109.29M | (15.27K) |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 58.39M | (102.07K) | 0 | 109.29M | (15.27K) |
| Effect of Forex Changes | 0 | 50.39K | 0 | 0 | 0 |
| Net Change in Cash | 49.34M | (14.14M) | (21.05M) | 79.98M | (28.43M) |
| Free Cash Flow | (9.05M) | (14.09M) | (21.05M) | (29.31M) | (26.42M) |
Context Therapeutics Inc.
NASDAQ:CNTX
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.